BEIJING, China, 17 October 2023 – Sinotau Pharmaceutical Group and the British molecular imaging company Blue Earth Diagnostics Ltd are announcing an exclusive strategic agreement for the development, production, and commercialization of the innovative PSMA-targeted PET imaging agent flotufolastat (18F) in China. Flotufolastat (18F) is an optimized positron emission tomography (PET) imaging agent designed to target prostate-specific membrane antigen (PSMA) positive lesions, indicated […]
BEIJING, China, 21-23 September 2023 – The 2023 Academic Annual Meeting of the Chinese Society of Nuclear Medicine was successfully held in the ancient capital Xi’an, where experts and scholars in nuclear medicine and related fields, excellent companies and industry elites gathered together. As a leading company of innovative radiopharmaceuticals, Sinotau also participated in this event. The conference was organized […]
Beijing, China, 15 September, 2023 – Sinotau’s radiopharmaceutical product Florbetaben F-18 (with Chinese trade name 欧韦宁®) received regulatory approval from National Medical Products Administration (NMPA) in China. Florbetaben F 18 injection is a radiotracer used for PET scanning of the brain, which can be used for the diagnosis, differential diagnosis and therapeutic evaluation of AD by determining […]
On September 12, the first commercialized drug of Sinotau, adenosine Injection(with Chinese trade name 欧达乐®, 20ml:60mg), was supplied to major hospitals nationwide, and formally entered the domestic clinical application. Adenosine injection is the classic drug of choice for drug loading, which was approved by the National Drug Administration (NMPA) for marketing license in January this […]
Beijing, China, the morning of 30 August, 2023-The initiation meeting of the Phase I/II clinical study of [177Lu]Lu-XT033 Injection initiated by Sinotau was successfully held at Beijing Cancer Hospital. This clinical study is to evaluate the safety and tolerability, radiation dosimetry and pharmacokinetic profile, and efficacy of [177Lu]Lu-XT033 Injection in patients with metastatic prostate cancer. […]
Sinotau Pharmaceutical Group, a leading enterprise in targeted radionuclide theranostics, recently announced completion for a new round of financing over RMB1.1 billion. This round of financing was invested by many national organizations, industry groups and well-known investment institutions, including SDIC Venture Capital, Goldstone, China Structural Reform Fund, Genertec Venture Capital, CITIC Securities, etc. China Life Private […]
24-27, June, 2023, the annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) was held in Chicago, USA. The SNMMI annual meeting is currently one of the largest and most influential academic conferences in the field of nuclear medicine and molecular imaging around the world, providing an in-depth understanding of the latest developments […]
On April 26, Jiangsu Sinotau Molecular Imaging Technology Co., Ltd. (“Jiangsu Sinotau”), a Sinotau’s subsidiary company, officially obtained the “Radiation Safety License” by the Department of Ecology and Environment of Jiangsu Province. The successful obtaining of the “Radiation Safety License” indicates that Jiangsu Sinotau has the qualification to use radiological devices, and produce, use and […]
On February 7, Beijing time, Lantheus, a Nasdaq-listed company, acquired Cerveau, a Sinotau’s joint venture, for an upfront payment and potential additional development and commercial milestone payments. This transaction is an important milestone in the development of molecular imaging in Alzheimer’s disease (AD). The main asset of Cerveau is the global rights of MK-6240, […]
Today, the product adenosine injection was approved for marketing by the National Medical Products Administration (NMPA) for myocardial perfusion imaging and echocardiographic drug loading tests to aid in the diagnosis of coronary artery disease. This is the only loading drug with both indications in China, providing a new option for non-invasive examination of myocardial ischemia […]
On December 28, 2022, the clinical trial application for [177Lu]Lu-XT033 injection, a class I new drug developed by Sinotau, was approved, which means [177Lu]Lu-XT033 is one step closer to commercialization and clinical application. The project has already initiated ethical filing and other preparations, and will advance to clinical enrollment as soon as possible. [177Lu]Lu-XT033 injection, which […]
Guangdong Sinotau Molecular Imaging Technology Co., Ltd., a subsidiary of Sinotau, has successfully obtained the “Radiopharmaceutical Production License” A certificate, which means Guangdong Sinotau Molecular Imaging Technology Co., Ltd. has the production site qualification of radiopharmaceuticals. This is also the second qualification certificate of radiopharmaceutical production license obtained by Sinotau, which provides GMP-compliant premises and facilities for the […]